Skip to main content
. Author manuscript; available in PMC: 2018 May 9.
Published in final edited form as: N Engl J Med. 2017 Nov 9;377(19):1836–1846. doi: 10.1056/NEJMoa1701830

Figure 2. Association between Pathological Nodal Status and the Risk of Distant Recurrence or Death from Breast Cancer during the 20-Year Study Period.

Figure 2

Shown are data regarding the risk of distant recurrence (Panel A) and death from breast cancer (Panel B) among 74,194 women with ER-positive T1 or T2 disease who were enrolled in 78 trials at year 0 and were scheduled to receive 5 years of endocrine therapy. (Data for another 10,200 women who enrolled in 10 trials after year 0 are not shown here.) The risk was calculated according to the patients’ pathological nodal status at the time of diagnosis: N0, N1–3, or N4–9. The number of events and annual rate are shown for the preceding period (e.g., data for years 0 to 4 are shown at 5 years). The I bars indicate 95% confidence intervals. The dashed lines indicate that the event rate is for the whole 5-year period, rather than for individual years, as is otherwise shown. The annual rate of death from breast cancer was estimated by subtracting the death rate in women without recurrence from the rate in all women.